This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this presentation are based on Quanterix' expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward- looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Confidential
2
O U R M I S S I O N
Ultrasensitive biomarker detection to transform the future of healthcare
(1)
INSTRUMENTS
Placements (2)
ACCELERATOR
Projects (2)
GEOGRAPHY
NA 60%
Europe 30%
Asia 10%
CUSTOMER
Academia 55% Pharma / CROs 45%
BIOMARKERS
Cumulative (2)
PUBLICATIONS
Cumulative (2)
FY2021 actuals $105M (excluding Radx)
All values are an approximation as of year end 2022
3
Key Messages
Our unmatched Simoa technology is a key competitive advantage for continued market leadership
We are early in penetration of a $75B discovery to diagnostics proteomics market opportunity
Our strategy is to deliver novel biomarker detection to unlock proteomics research and translate those discoveries to improve human health.
Early focus on an emerging neuro market and enabling field on the brink of breakthrough therapies for Alzheimer's and neurodegenerative diseases.
>875 instruments installed, unique technology with strong IP, one of a few companies with commercial scale, and well positioned to extend our leadership position in proteomics.
4
Single Molecule Array Technology (Simoa)
Analog
Traditional ELISA assay
Digital
Millions of molecules needed to reach detection limit
SUBSTRATE
0 pM
10 pM
0 aM
3.5 aM
350 aM
3.5 fM
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Quanterix Corporation published this content on 12 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2023 20:09:04 UTC.
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.
QUANTERIX CORPORATION 
